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The pilosebaceous apparatus is a target or-
gan under androgea influence. Acne and hirsu-
tism are found to occur in clinical situations as-
sociated with excessive androgen secretion. In
several instances, however, no androgen excess
can be demonstrated in patients with acne and
hirsutism within the limitations of our present
knowledge and techniques. It has been sug-
gested that in these situations the possibility
of increased end organ sensitivity to andro-
gens be given serious consideration (1). The
long search for an agent that could neutralize
this effect culminated in a detailed study of l7a-
methyl-B-nortcstosteronc (Fig. 1). This syn-
thetic compound was reported to have anti-
androgenic properties in rats and mice by
Saunders et al (2). Studies done in our lab-
oratory on experimental animals confirmed this
antiandrogenic activity and indicated that it
also possessed weak antigonadotropic and pos-
sibly weak androgcnic properties (3). Competi-
tion for receptor sites at the target organ level
is thought to be its mechanism of action as an
antiandrogen. In the human, 17a-mcthyl-B-
nortestosterone was found effective in the
management of acne and hirsutism and the re-
sults were reported in earlier papers (4, 5).
Quantitative data were obtained using facial
hair collection or sebum analysis in a limited
number of patients. In the majority of cases the
main criterion used for improvement in acne
was the disappearance of existing lesions and
marked lessening of new eruptions. Improve-
ment in hirsutism was judged in general by
decrease in hair growth and the frequency of
shaving.
The purpose of this paper is to present the
results obtained in 55 patients after the with-
drawal of the drug. The study is largely con-
fined to young women and only two males. The
use of l7ci-methyl-B-nortestosterone in the
male may be limited by the finding by Caplan
(6) of gynecomastia in 12 of 13 cases, although
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this complication was not observed in our 2
cases. While Caplan did not observe any real
improvement of acne, an excellent response was
obtained in our 2 male patients. The improved
condition during therapy as compared to the
return of the pretreatment status some weeks
or months after discontinuation of the drug,
seemed to lend weight to the efficacy of the
antiandrogenic agent.
MATEIHAL AND METHOD5
17a-methyl-B-nortestosterone1 was administered
orally to 55 patients (53 females and 2 males) in
daily doscs ranging from 50 to 600 mg for periods
of 1 to 22 months, beginning with a 50 mg dose
and increasing by increments of 50—100 mg. While
on this regimen, no other forms of medication were
administered. Complete blood counts, urinalysis,
coagulation time, SCOT, SGPT, BUN, alkaline
phosphatase and serum creatinine were performed
in all the patients at various intervals of time in
order to study hepatic, renal and hemepoietic
function during treatment. In several patients
the estimation of 17 ketosteroids, 17 ketogenie
steroids and steroid fractionations were carried
out. The results were reported earlier (5).
RESULTS
The effect of the administration of this com-
pound on acne and hirsutism is shown in Table
I. Although the total number of patients was
55, most of the patients had a combination of
acne and hirsutism, thus giving a total of 75
points of study. Although the criterion of im-
provement was based on subjective judgement,
nonetheless the results were quite obvious.
Beneficial results were observed in 26 of 35
patients with acne (74.3%). Lessening of hir-
sutism was noted in 21 of the 40 patients
studied (52.5%). The best effects were achieved
with dosages ranging from 200 to 400 mg/day.
Improvement in acne frequently was noted
within a short time of one or more weeks. The
more severe cases of acne showed the greatest
improvement, while the diminution of hirsutism
was more gradual and not related to the degree
of hypertrichosis.
1 17a-methyl-B-nortestosterone used in this
study was supplied by the Smith Kline & French
Laboratories, Philadelphia, Pa.
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The interpretation of the results shown in
Table I could be subject to two major criti-
cisms. Firstly, the observations in Table I
were subjective in many instances for want of
distinct criteria for the quantitative evaluation
of acne and hirsutism. Secondly, a double blind
study for the efficacy of the drug would have
been of great value. We had hoped to carry out
a double blind study with 17a-mcthyl-B-
nortcstostcronc during the second phase of our
clinical trials but the drug was withdrawn from
clinical trials pending further animal experi-
mentation. In the absence of a double blind
study to evaluate the efficacy of 17a-methyl-B-
nortestosteronc, it may be helpful to mention
that the usc of oral contraceptives has been
tried extensively by many investigators for the
management of acne (7—10). In a study with
the classical contraceptive pill and the se-
quential form of the pill in our clinic, done
under the same conditions as with 17a-mcthyl-
B-nortestostcronc, the improvement in acne
was noted to be 50% in cases with the classical
and 46.8% with the sequential form (11). The
beneficial outcome with 17a-mcthyl-B-nortcs-
tostcrone was found to be 74.3%. The compari-
son of the effect of this agent with those of
oral contraceptive pills, offers in a measure
additional confirmation to its efficacy.
Further confirmation of its efficacy was ob-
tained by follow up studies after termination
of therapy at varying intervals ranging from
a few months to two years. The regressive
changes noted on therapy were in almost every
instance confined to the period of therapy
and a short interval thereafter. Recurrence
took place in all the patients with acne and
in most of those with hirsutism (Table II).
The clinical laboratory tests were within
TABLE I
Results under treatment with 17a-methyl-B-
nortestosterone
Ro.of cases Doubtful beneficial Improvement
effects cc no chonge
ACRE 35 9
RIRSUTISM 40
TOTAL 75
TABLE II
Results after discontinuation of the treatment
with 1 7cc-methyt-B-nortestosteronc
hR NUT I SM
TOTAL
No.of canes Sc change Reappearance
of nymptcicn
26 — 26
21 8 13
47 8 39
range of normal. Of interest was the uniform
increase in urinary 17 kctostcroids. Interference
of the drug in the routine method of Drektcr
et al. (12) for total kctostcroids was shown
to be responsible for this effect (5). Tolerance
for the age and absence of evident toxicity per-
mitted its use for prolonged periods of time.
cONcLIJsToNs
The introduction of an antiandrogen into our
therapeutic armamcntarium is a goal long
sought. This agent, 17a-mcthyl-B-nortcstostcr-
one was the first such preparation assayed
clinically. The relative absence of untoward re-
actions and the lack of derangement in the
other endocrine systems were features of tius
drug. We can conclude that the rational man-
agement of the manifestations of increased
sensitivity to endogenous androgens is through
the administration of an antiandrogcn. The
excellent results obtained, though temporary,
offer promise to the long time approach of the
treatment of acne and idiopathic hirsutism. It
is hoped that continued search for the ideal
antiandrogcn will continue.
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